A Phase 1, Open-Label, Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inhibitor (Itraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
Price : $35 *
At a glance
- Drugs Mifepristone (Primary) ; Itraconazole
- Indications Breast cancer; Cushing syndrome; Induced abortion; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 21 Feb 2018 Status changed from recruiting to completed.
- 24 Oct 2017 Planned primary completion date changed from 12 Oct 2017 to 1 Nov 2017.
- 29 Aug 2017 New trial record